Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 15, 2025, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 15, 2025, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg".